Senseonics Holdings, Inc. (NASDAQ:SENS – Get Free Report)’s stock price passed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $9.24 and traded as low as $8.76. Senseonics shares last traded at $8.90, with a volume of 1,325,106 shares changing hands.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the stock. Stifel Nicolaus reaffirmed a “hold” rating and issued a $10.00 target price (up from $9.00) on shares of Senseonics in a report on Tuesday, November 10th. Barclays boosted their price target on shares of Senseonics from $10.00 to $11.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 10th. Mizuho upped their price objective on shares of Senseonics from $18.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 10th. TD Cowen raised their price objective on shares of Senseonics from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Senseonics in a research note on Tuesday, November 10th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Senseonics currently has a consensus rating of “Hold” and a consensus price target of $14.40.
View Our Latest Analysis on Senseonics
Senseonics Price Performance
The company’s 50 day simple moving average is $9.24 and its 200 day simple moving average is $7.38. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.92 and a quick ratio of 5.60. The stock has a market cap of $487.54 million, a P/E ratio of -3.87 and a beta of 1.04.
Senseonics (NASDAQ:SENS – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). The business had revenue of $19.56 million during the quarter. Senseonics had a negative return on equity of 186.11% and a negative net margin of 204.01%. As a group, equities analysts forecast that Senseonics Holdings, Inc. will post -2.20 earnings per share for the current year.
Insider Transactions at Senseonics
In other Senseonics news, Director Douglas Roeder bought 17,041 shares of the firm’s stock in a transaction on Friday, November 13th. The shares were purchased at an average price of $10.32 per share, for a total transaction of $175,863.12. Following the transaction, the director directly owned 189,712 shares in the company, valued at approximately $1,957,827.84. This trade represents a 9.87% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.70% of the stock is owned by company insiders.
Institutional Trading of Senseonics
Hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. lifted its holdings in shares of Senseonics by 60.6% during the third quarter. Goldman Sachs Group Inc. now owns 371,706 shares of the company’s stock worth $3,780,000 after purchasing an additional 140,197 shares during the period. Empowered Funds LLC bought a new stake in shares of Senseonics in the third quarter worth $621,000. Ieq Capital LLC acquired a new stake in Senseonics in the third quarter valued at $215,000. StoneX Group Inc. bought a new position in Senseonics during the 3rd quarter worth $128,000. Finally, Traynor Capital Management Inc. bought a new position in Senseonics during the 3rd quarter worth $152,000. Institutional investors and hedge funds own 12.36% of the company’s stock.
About Senseonics
Senseonics Holdings, Inc. develops continuous glucose monitoring (CGM) technology for people with diabetes. Its Eversense systems use a small sensor implanted under the skin to measure glucose levels, an external wearable transmitter to send readings, and a mobile app to display data and provide alerts. The company’s product line includes implantable CGM systems designed for extended wear, including the Eversense 365 system, which is designed to last up to one year. Unlike many CGM products that use sensors replaced more frequently, Eversense sensors are inserted and removed by a healthcare professional.
Recommended Stories
- Five stocks we like better than Senseonics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.
